Gossamer Bio announced terms for it's $230 Million IPO on 1/23/19. The company plans to offer 14.4 million shares at $16 per share. Insiders have expressed an interest in acquiring $100 million of the offering. The IPO will attempt to bypass the government shutdown via a rarely used rule that allows a company to file with a fixed price and begin trading 20 days later.
 
Gossamer is a clinical stage company that is developing therapeutics for a diverse range of disease states including: asthma, pulmonary arterial hypertension, IBD, cancer, etc. They have eight development programs under way.

It's lead projects are GB001 for moderate-to-severe eosinophilic asthma and other allergic conditions, GB002 for pulmonary arterial hypertension, GB004 for IBD.

In July of of 2018 the company announced a $230 million series B round. Participants included, Hillhouse capital, a wholly-owned subsidiary of the Abu Dhabi Investment Authority (ADIA), Invus, The Baupost Group and Polaris Partners, among others.